Moomoo AI 已提取核心信息
AbbVie Inc. has successfully priced a multi-tranche offering of Senior Notes totaling $15 billion on February 22, 2024. The offering includes various maturities: $2.25 billion due 2027, $2.5 billion due 2029, $2 billion due 2031, $3 billion due 2034, $750 million due 2044, $3 billion due 2054, and $1.5 billion due 2064, with interest rates ranging from 4.800% to 5.500%. The trade date was February 22, 2024, with a settlement date set for February 26, 2024. The notes received ratings of A3 (Stable) from Moody's and A- (Stable) from Standard & Poor's. The offering was registered with the SEC and managed by a syndicate of banks, including Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup, among others. The notes are expected to be delivered on a T+2 basis, with interest payments commencing on September 15, 2024. This strategic move by AbbVie aims to diversify its funding sources and extend its debt maturity profile.
AbbVie Inc. has successfully priced a multi-tranche offering of Senior Notes totaling $15 billion on February 22, 2024. The offering includes various maturities: $2.25 billion due 2027, $2.5 billion due 2029, $2 billion due 2031, $3 billion due 2034, $750 million due 2044, $3 billion due 2054, and $1.5 billion due 2064, with interest rates ranging from 4.800% to 5.500%. The trade date was February 22, 2024, with a settlement date set for February 26, 2024. The notes received ratings of A3 (Stable) from Moody's and A- (Stable) from Standard & Poor's. The offering was registered with the SEC and managed by a syndicate of banks, including Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup, among others. The notes are expected to be delivered on a T+2 basis, with interest payments commencing on September 15, 2024. This strategic move by AbbVie aims to diversify its funding sources and extend its debt maturity profile.
艾伯维公司已于2024年2月22日成功对总额为150亿美元的多批优先票据进行了定价。此次发行包括各种到期日：2027年到期的22.5亿美元、2029年到期的25亿美元、2031年到期的20亿美元、2034年到期的30亿美元、2044年到期的7.5亿美元、2054年到期的30亿美元和2064年到期的15亿美元，利率从4.800％到5.500％不等。交易日期为2024年2月22日，结算日期定为2024年2月26日。这些票据获得穆迪的A3（稳定）评级，标准普尔的评级为A-（稳定）。此次发行已在美国证券交易委员会注册，由包括摩根士丹利、摩根大通、美银证券和花旗集团等在内的银行集团管理。这些票据预计将在T+2基础上交付，利息支付将于2024年9月15日开始。艾伯维的这一战略举措旨在分散其资金来源并扩大其债务到期日范围。
艾伯维公司已于2024年2月22日成功对总额为150亿美元的多批优先票据进行了定价。此次发行包括各种到期日：2027年到期的22.5亿美元、2029年到期的25亿美元、2031年到期的20亿美元、2034年到期的30亿美元、2044年到期的7.5亿美元、2054年到期的30亿美元和2064年到期的15亿美元，利率从4.800％到5.500％不等。交易日期为2024年2月22日，结算日期定为2024年2月26日。这些票据获得穆迪的A3（稳定）评级，标准普尔的评级为A-（稳定）。此次发行已在美国证券交易委员会注册，由包括摩根士丹利、摩根大通、美银证券和花旗集团等在内的银行集团管理。这些票据预计将在T+2基础上交付，利息支付将于2024年9月15日开始。艾伯维的这一战略举措旨在分散其资金来源并扩大其债务到期日范围。
有用
没用